Phaseline

Targets › RAF1

RAF1 (RAF proto-oncogene serine/threonine-protein kinase): drug programs, companies and trials

11 programs from 10 companies in 81 trials: 53 Phase 2, 21 Phase 1, 7 Phase 3; Oncology; next expected readout Nov 2026.

Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation. RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that comprises a sequential…. (UniProt, P04049)

Open in Phaseline: the race on RAF1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
ErascaNaporafenib
B-raf/RAF proto-oncogene serine/threonine-protein kinase inhibitor
RAF1, BRAFPhase 3Advanced or Metastatic NRAS-mutant Melanoma; Advanced or Metastatic Solid TumorsDec 2026
Day One BiopharmaceuticalsTovorafenib
RAF serine/threonine protein kinase inhibitor
RAF1, BRAF, ARAFPhase 3Low-grade Glioma; Craniopharyngioma, Child; Recurrent Langerhans Cell Histiocytosis; Hairy Cell LeukemiaMay 2027
RocheSorafenib
Serine/threonine-protein kinase RAF inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor
RAF1, PDGFRB, KIT, FLT3, BRAFPhase 3Unresectable Hepatocellular Carcinoma; AML (Acute Myeloid Leukemia); Locally Advanced Thyroid Gland Carcinoma; Hepatocellular Carcinoma …–
The First Affiliated Hospital with Nanjing Medical UniversityDonafenib
RAF kinase inhibitor
RAF1Phase 2Biliary Malignant TumorsNov 2026
NovartisNaporafenib (LXH254)
B-raf/RAF proto-oncogene serine/threonine-protein kinase inhibitor
RAF1, BRAFPhase 2Melanoma; EGFR-mutant Non-small Cell Lung CancerFeb 2027
National Cancer Institute (NCI)Sorafenib Tosylate
Serine/threonine-protein kinase RAF inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor
RAF1, PDGFRB, KIT, FLT3, BRAFPhase 2Gastrointestinal Stromal Tumor; Acute Myeloid Leukemia; Advanced Malignant Solid NeoplasmMar 2027
BayerRegorafenib (BAY73)
Tyrosine-protein kinase ABL inhibitor; Serine/threonine-protein kinase RAF inhibitor; Stem cell growth factor receptor inhibitor
ABL1, RAF1, KIT, FGFR1, MAPK11Phase 2Solid Malignant Tumors; Metastatic Colorectal Cancer (mCRC); Colorectal Cancer Liver Metastases; Colorectal Cancer Metastatic …Apr 2028
Hanmi Pharmaceutical CompanyBelvarafenib
RAF serine/threonine protein kinase inhibitor
RAF1, BRAF, ARAFPhase 2Advanced or Metastatic MelanomaSep 2029
RocheBelvarafenib
RAF serine/threonine protein kinase inhibitor
RAF1, BRAF, ARAFPhase 1Melanoma; Primary Brain TumorDec 2026
Nested TherapeuticsNST-628
non-covalent pan-RAF/MEK dual molecular glue targeting RAF and MEK nodes of MAPK pathway
RAF1, MAP2K1Phase 1OncologyNov 2028
IpsenTovorafenib
RAF serine/threonine protein kinase inhibitor
RAF1, BRAF, ARAFPhase 1Low-grade GliomaJul 2030

Conditions

Hepatocellular Carcinoma (7) Low-grade Glioma (3) Colorectal Cancer Metastatic (2) Melanoma Stage III (2) Unresectable Hepatocellular Carcinoma (2) Gastrointestinal Stromal Tumors (2) Ovarian Cancer (2) Colorectal Cancer (2) Metastatic Colorectal Cancer (2) Hepato Cellular Carcinoma (HCC) (2) Melanoma (2) Neuroblastoma (2)

Modalities

small molecule (9), mixed (2)

Companies

Roche (2) The First Affiliated Hospital with Nanjing Medical University (1) Erasca (1) National Cancer Institute (NCI) (1) Bayer (1) Day One Biopharmaceuticals (1) Nested Therapeutics (1) Ipsen (1) Novartis (1) Hanmi Pharmaceutical Company (1)

Related targets

BRAF (8) ARAF (4) KIT (3) PDGFRB (2) FLT3 (2) ABL1 (1) FGFR1 (1) MAPK11 (1) MAP2K1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.